Targeting cytokine and chemokine signaling pathways for cancer therapy
Cytokines are critical in regulating immune responses and cellular behavior, playing dual
roles in both normal physiology and the pathology of diseases such as cancer. These …
roles in both normal physiology and the pathology of diseases such as cancer. These …
Signal pathways of melanoma and targeted therapy
W Guo, H Wang, C Li - Signal transduction and targeted therapy, 2021 - nature.com
Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …
[HTML][HTML] Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
O Michielin, ACJ Van Akkooi, PA Ascierto, R Dummer… - Annals of …, 2019 - Elsevier
This ESMO Clinical Practice Guidelines provide updated recommendations on management
of cutaneous melanoma (diagnosis, treatment and follow-up), compiled by a …
of cutaneous melanoma (diagnosis, treatment and follow-up), compiled by a …
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Background The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to
prolong progression-free and overall survival among patients with advanced melanoma. We …
prolong progression-free and overall survival among patients with advanced melanoma. We …
[HTML][HTML] Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy
AMM Eggermont, V Chiarion-Sileni… - … England Journal of …, 2016 - Mass Medical Soc
Background On the basis of data from a phase 2 trial that compared the checkpoint inhibitor
ipilimumab at doses of 0.3 mg, 3 mg, and 10 mg per kilogram of body weight in patients with …
ipilimumab at doses of 0.3 mg, 3 mg, and 10 mg per kilogram of body weight in patients with …
Systemic therapy for melanoma: ASCO guideline
R Seth, H Messersmith, V Kaur, JM Kirkwood… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE To provide guidance to clinicians regarding the use of systemic therapy for
melanoma. METHODS ASCO convened an Expert Panel and conducted a systematic …
melanoma. METHODS ASCO convened an Expert Panel and conducted a systematic …
Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology
DG Coit, JA Thompson, MR Albertini, C Barker… - Journal of the National …, 2019 - jnccn.org
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous
melanoma have been significantly revised over the past few years in response to emerging …
melanoma have been significantly revised over the past few years in response to emerging …
Hyperprogressive disease: recognizing a novel pattern to improve patient management
S Champiat, R Ferrara, C Massard, B Besse… - Nature reviews Clinical …, 2018 - nature.com
Abstract Anti-PD-1/PD-L1 monoclonal antibodies have substantially improved the overall
survival of a subset of patients across multiple solid tumour types, but other patients can …
survival of a subset of patients across multiple solid tumour types, but other patients can …
Systemic therapy for melanoma: ASCO guideline update
R Seth, SS Agarwala, H Messersmith… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE To provide guidance to clinicians regarding the use of systemic therapy for
melanoma. METHODS American Society of Clinical Oncology convened an Expert Panel …
melanoma. METHODS American Society of Clinical Oncology convened an Expert Panel …
[HTML][HTML] Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape
Cancer immunotherapy is now established as a powerful way to treat cancer. The recent
clinical success of immune checkpoint blockade (antagonists of CTLA-4, PD-1 and PD-L1) …
clinical success of immune checkpoint blockade (antagonists of CTLA-4, PD-1 and PD-L1) …